RARE Daily

Keros Raises $130 Million to Advance Hematological and Musculoskeletal Pipeline

November 13, 2020

Rare Daily Staff

Keros Therapeutics said it priced a public offering of 2.6 million shares of its common stock at $50.00 per share to raise $130 million. In addition, Keros has granted the underwriters a 30-day option to purchase up to an additional 390,000 shares of common stock at the public offering price, less the underwriting discounts and commissions.

The company, focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need, will use the proceeds to advance its programs that are based on understanding the role of the Transforming Growth Factor-Beta, or TGF-ß, family of proteins, which are master regulators of red blood cell and platelet production as well as of the growth, repair and maintenance of muscle and bone.

Keros’ lead protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes and in patients with myelofibrosis, both rare disorders. It is currently being studied in a phase 2 trial in myelodysplastic syndromes.

Keros’ lead small molecule product candidate, KER-047, is being developed for the treatment of anemia resulting from elevated levels of hepcidin, the key regulator of iron absorption and recycling, as well as for the treatment of fibrodysplasia ossificans progressive (FOP), a rare genetic diseases where muscle connective tissues gradually become replaced by bone.

Keros’ preclinical candidate, KER-012, is being developed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension.


Stay Connected

Sign up for updates straight to your inbox.